Integrated Formulation Development: Solubility Enhancement, Modified Release and AI-Informed Drug Development - Paris

Poor drug solubility or the need for controlled or modified release remain common formulation optimisation considerations in drug development. However, traditional industry structures mean that this process is constrained by long timelines and reliance on predictive laboratory and preclinical models.

Join us for a full-day event dedicated to Solubility Enhancement, Modified Release and AI-Informed Drug Development on September 24th in Paris, France. 

This seminar will explore how Quotient Sciences’ Translational Pharmaceutics® platform integrates formulation development, GMP manufacturing, and clinical testing to accelerate the selection and optimisation of commercial intent formulations; a capability that can be further enhanced by the application of machine learning to the formulation development process.

The first talk will focus on practical approaches to solubility enhancement, including the selection and application of enabling technologies to improve oral exposure for poorly soluble molecules. 

The second talk will examine modified release formulation development and the emerging role of AI-informed formulation design, highlighting how data-driven tools can help explore formulation options more efficiently, reduce experimental burden, and support more informed decisions as molecules move into and through clinical development. 

Learning Objectives

• Understand how Translational Pharmaceutics® can be applied to accelerate formulation selection and optimisation by integrating formulation development, manufacturing, and clinical data.
• Recognise key formulation strategies for addressing poor drug solubility, including when and how enabling technologies may be used to improve bioavailability and support early clinical development.
• Explore how formulation design space can be applied to develop and optimise modified release formulations to meet target product performance objectives
• Hear how Quotient is pioneering AI-informed formulation development to support faster, more data-driven formulation design by reducing experimental burden, and improving decision confidence.
• Identify how integrated, adaptive development approaches can help reduce risk, conserve drug substance, and shorten timelines from formulation concept to clinical evaluation. 

Register now